

PHARMACEUTICAL ECONOMICS  
AND POLICY

---

Second Edition

Stuart O. Schweitzer

OXFORD  
UNIVERSITY PRESS  
2007

**OXFORD**  
UNIVERSITY PRESS

Oxford University Press, Inc., publishes works that further  
Oxford University's objective of excellence  
in research, scholarship, and education.

Oxford New York  
Auckland Cape Town Dares Salaam Hong Kong Karachi  
Kuala Lumpur Madrid Melbourne Mexico City Nairobi  
New Delhi Shanghai Taipei Toronto

With offices in  
Argentina Austria Brazil Chile Czech Republic France Greece  
Guatemala Hungary Italy Japan Poland Portugal Singapore  
South Korea Switzerland Thailand Turkey Ukraine Vietnam

Copyright © 2007 by Oxford University Press.

Published by Oxford University Press, Inc.  
198 Madison Avenue, New York, New York 10016  
www.oup.com

Oxford is a registered trademark of Oxford University Press

All rights reserved. No part of this publication may be reproduced,  
stored in a retrieval system, or transmitted, in any form or by any means,  
electronic, mechanical, photocopying, recording, or otherwise,  
without the prior permission of Oxford University Press.

Library of Congress Cataloging-in-Publication Data  
Schweitzer, Stuart O.  
Pharmaceutical economics and policy / Stuart O. Schweitzer.—2nd ed.  
p. : cm.

Includes bibliographical references and index.  
ISBN 978-0-19-530095-6

1. Pharmaceutical industry—United States. 2. Pharmaceutical policy—U.  
3. Pharmaceutical industry.

[DNLM: 1. Economics, Pharmaceutical—United States. 2. Drug Industry  
3. Public Policy—United States. QV 736 S413p 2006] I. Title.

HD9666.5.S385 2006  
338.4'761510973—dc22 2006003075

9 8 7 6 5 4 3 2

## Contents

### Introduction

*The Supply of Pharmaceuticals*

*The Demand for Pharmaceuticals*

*Pharmaceutical Prices*

*The Multinational Pharmaceutical Industry*

*International Price Comparisons*

*Timing of Pharmaceutical Approvals*

*Government Intervention in the Pharmaceutical Sector*

### Part I. The Industry

#### 1 The Pharmaceutical Industry

*Pharmaceutical Research and Development*

*The Competitive Structure of the Pharmaceutical Industry*

*Pharmaceutical Research and Development and Prices*

*The Pharmaceutical Research Process*

*Product Liability*

*Conclusions*

#### 2 The Biotechnology Industry

*Background*

*Product Development in the Biotechnology Industry*

*The Natural History of Biotechnology Firms*

*Case Studies of Alliances*

*Regulation*

*Case Studies of Biotechnology Firm Growth*

*Conclusions*

|   |  |     |
|---|--|-----|
| 3 | <b>Other Firms in the Pharmaceutical Industry</b>                  | 63  |
|   | <i>Generic Drugs and Their Manufacturers</i>                       | 63  |
|   | <i>Outsourcing Firms</i>   | 68  |
|   | <i>Conclusions</i>   | 78  |
| 4 | <b>Marketing Pharmaceuticals</b>                                   | 82  |
|   | <i>Size of Marketing Effort</i>                                    | 85  |
|   | <i>Does It Work?</i>   | 85  |
|   | <i>Types of Promotion</i>  | 87  |
|   | <i>Disguising Marketing as Research</i>                            | 93  |
|   | <i>Marketing in an Era of Managed Care</i>                         | 94  |
|   | <i>Pharmacy Benefit Managers</i>                                   | 95  |
|   | <i>Direct-to-Consumer Advertising</i>                              | 97  |
|   | <i>Over-the-Counter Drugs</i>                                      | 100 |
|   | <i>Joint Marketing</i>   | 103 |
|   | <i>Disease Management</i>  | 103 |
|   | <i>Roles of the U.S. Food and Drug Administration in Marketing</i> | 104 |
|   | <i>False and Misleading Claims</i>                                 | 105 |

## Part II. The Consumer

|   |  |     |
|---|--|-----|
| 5 | <b>The Demand for Pharmaceuticals</b>                      | 115 |
|   | <i>How Is Demand Determined?</i>                           | 116 |
|   | <i>The Changing Structure of the Pharmaceutical Market</i> | 117 |
|   | <i>Conclusions</i>   | 131 |

## Part III. The Market

|   |   |     |
|---|---|-----|
| 6 | <b>Pharmaceutical Prices</b>  | 137 |
|   | <i>The Problem of Pharmaceutical Prices</i>                           | 138 |
|   | <i>Pharmaceutical Prices over Time</i>                                | 139 |
|   | <i>Measuring Drug Prices</i>  | 141 |
|   | <i>How Are Drug Prices Determined?</i>                                | 143 |
|   | <i>Cost Structure of Pharmaceutical Firms</i>                         | 144 |
|   | <i>Is the Pharmaceutical Industry Monopolistic?</i>                   | 149 |
|   | <i>How Drug Quality Influences Price</i>                              | 153 |
| 7 | <b>The Worldwide Market for Pharmaceuticals</b>                       | 157 |
|   | <i>Geographic Patterns of Pharmaceutical Production and Sales</i>     | 158 |
|   | <i>Pharmaceutical Research and Development: An International View</i> | 159 |
|   | <i>Does Government Drug Price Setting Influence R&amp;D?</i>          | 166 |
|   | <i>Worldwide Manufacturing and Sales</i>                              | 167 |
|   | <i>Access to Appropriate Drugs in Developing Countries</i>            | 170 |
|   | <i>Effect of the World Trade Organization Treaty</i>                  | 173 |
| 8 | <b>Pricing Pharmaceuticals in a World Environment</b>                 | 177 |
|   | <i>Why Do Drug Prices Vary Across Country?</i>                        | 178 |
|   | <i>Comparisons of International Drug Prices</i>                       | 180 |
|   | <i>How Do We Measure Drug Prices across Countries?</i>                | 184 |

*Why Drug Price Differences Persist*  
*Policy Implications*

|   |   |
|---|---|
| 9 | <b>The Timing of Drug Approvals in the United States</b>  |
|   | <i>The Timing of Pharmaceutical Approvals and Hurdles</i> |
|   | <i>The Drug Approval Process in the United States</i>     |
|   | <i>Recent Initiatives to Expedite Drug Approvals</i>      |
|   | <i>Is There a U.S. Drug Lag?</i>                          |

## Part IV. Intervention in the Pharmaceutical Industry: Public and Private

|    |  |
|----|--|
| 10 | <b>Pharmaceutical Regulation and Cost Containment by the Public Sector</b> |
|    | <i>Evolution of the U.S. Food and Drug Administration</i>                  |
|    | <i>Medicaid</i>  |
|    | <i>State Cost-Containment Efforts</i>                                      |
|    | <i>Medicare</i>  |
| 11 | <b>Regulation by the Private Sector</b>                                    |
|    | <i>Cost-Containment Mechanisms</i>   |
|    | <i>Cost Containment in Managed Care</i>                                    |
| 12 | <b>Pharmaceutical Regulation in Europe</b>                                 |
|    | <i>The Pharmaceutical Industry in Europe</i>                               |
|    | <i>History of Regulation in Europe</i>                                     |
|    | <i>Move Toward a Single Market</i>   |
|    | <i>Structure and Role of the European Medicines Agency</i>                 |
|    | <i>Drug Review under the European Medicines Directive</i>                  |
|    | <i>Current Regulatory Structure</i>  |
|    | <i>The Centralized Procedure for Marketing Authorization</i>               |
|    | <i>The Mutual-Recognition Procedure</i>                                    |
|    | <i>Performance of Europe's Centralized Drug Approval Procedure</i>         |
|    | <i>Rules on Labeling of Medicinal Products</i>                             |
|    | <i>Advertising Regulations</i>   |
|    | <i>Pharmacovigilance</i>   |
|    | <i>Generic Drugs</i>   |
| 13 | <b>Patent Protection</b>   |
|    | <i>Patent Law</i>  |
|    | <i>Patentability and Patent Categories</i>                                 |
|    | <i>How Are Patents Obtained?</i>   |
|    | <i>What Protection Does a Patent Confer?</i>                               |
|    | <i>Duration of Patent Protection</i>                                       |
|    | <i>Infringement of Patents</i>   |
|    | <i>International Patent Treaties</i>                                       |
|    | <i>Patent Procedures under International Conventions</i>                   |
|    | <i>Shortcomings of the Patent System</i>                                   |
|    | <i>Patents and Societal Choice</i>   |
|    | <i>Social Benefits of the Patent System</i>                                |

xiv Contents

|    |  |     |
|----|--|-----|
| 14 | Evaluating New Drugs   | 263 |
|    | <i>Optimizing Production of Health</i>   | 263 |
|    | <i>Cost-Benefit Analysis</i>   | 266 |
|    | <i>Cost-Effectiveness Analysis</i>   | 270 |
|    | <i>Cost-Utility Analysis</i>   | 272 |
|    | <i>Policy Applications</i>   | 274 |
|    | <i>Interpretation and Misinterpretation of Cost-Effectiveness Studies</i>        | 277 |
| 15 | Complementary and Alternative Medicines  | 280 |
|    | <i>Who Uses Complementary and Alternative Medicines?</i>                         | 282 |
|    | <i>Manufacturers and Distributors of Complementary and Alternative Medicines</i> | 282 |
|    | <i>Dietary Supplements</i>   | 283 |
|    | <i>Food Additives</i>  | 293 |
|    | <i>Medical Foods</i>   | 296 |
|    | <i>Concluding Remarks on Complementary and Alternative Medicines</i>             | 300 |
| 16 | Pharmaceuticals and Health Policy: A Look Ahead                                  | 304 |
|    | <i>Structure of the Pharmaceutical Industry</i>                                  | 304 |
|    | <i>Health System Reform</i>  | 306 |
|    | <i>Drug Prices</i>   | 308 |
|    | <i>Drug Imports</i>  | 308 |
|    | <i>Patent Protection</i>   | 309 |
|    | <i>Drug Approvals</i>  | 310 |
|    | <i>Managed Care and Restricted Access to Pharmaceuticals</i>                     | 311 |
|    | <i>The U.S. Food and Drug Administration</i>                                     | 313 |
|    | <i>Genetically Targeted Drugs</i>  | 314 |
|    | <i>Conclusions</i>   | 315 |
|    | Index  | 317 |

PHARMACEUTICAL ECONOMI

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.